NERV

Latest SEC Filings & News for NERV

1 most recent filing and news item mentioning NERV. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/NERV/news?limit=20"

Pull NERV filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
Earnings|Leadership|OtherAug 7, 2026Neutral

Minerva Neurosciences reports Q2 2026 results, update on roluperidone Phase 3 trial

Minerva Neurosciences provided an update on the confirmatory Phase 3 clinical trial of roluperidone for negative symptoms of schizophrenia, expecting topline efficacy data in the second half of 2027. The company announced the addition of experts to its Scientific Advisory Board.

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.